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Abstract
Renal cell carcinoma (RCC) accounts for 3% of all adult cancers and 85% of all kidney tumours. Incidence of RCC is lower in Asian region, 
particularly in India, probably due to lack of reporting. Most of the data about RCC are from Western countries; and data from India are scarce, 
especially regarding para-neoplastic syndromes. We sought to determine the epidemiology, clinicopathological profile and management of RCC 
in a tertiary care centre in Western India.
This was a retrospective study that involved data analysis of records of RCC patients who presented to our institution from April 2016 to Feb-
ruary 2020. Laboratory investigations, including tests for paraneoplastic syndrome (PNS), and relevant radiologic investigations were performed 
and treatment was offered according to the stage, patient factors and available modalities.
A total 142 RCC patients were included in the study. The median age of presentation was 58 years. Most of the patients (67%) were symptom-
atic, and 33% of the patients were asymptomatic, and the RCC was diagnosed incidentally. A large number of patients (56.3%) had PNS. The 
most common histopathologic type of RCC was clear cell carcinoma (68.8%), followed by papillary (20%) and chromophobe (8%) carcinoma. 
40% of carcinomas with sarcomatoid differentiation were seen in patients under 50 years of age. Two cases of multicystic RCC were both seen 
in patients less than 50 years of age. 65.5% of the patients presented at Stage 1 and 2. Most surgeries (71.2%) were done in a minimally invasive 
manner.
A significant number of patients were asymptomatic, in which RCC was detected incidentally. The age of presentation was earlier, yet the 
patients had a higher tumour stage. More than half  of the patients had PNSs. Despite growing trend towards Western data, the significantly 
higher number of patients with PNSs and early age of presentation suggest inherent differences in tumour biology, possibly related to differences 
in genetic and environmental factors.
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Introduction
Renal cell carcinoma (RCC) accounts for 3% of all adult can-
cers and 85% of all kidney tumours (1). Incidence of RCC is 
lower in Asian region, particularly in India, probably owing 
to lack of reporting (2). The incidence is expected to rise 
in India due to increasing life expectancy, rising awareness, 
better diagnostic facilities and growing prevalence of risk 
factors such as obesity (3). Most of the data about RCC are 
from Western countries; and data from India are scarce (4). 
Because the clinical spectrum of a disease may differ across 
the globe, this study was undertaken with the objectives of 
studying the demography, presentation and management of 
RCC at a referral centre located in western part of India, 
with the ultimate aim to comment on the clinical heterogene-
ity of the disease, if  any, and to fill the knowledge gap among 
researchers.
Methods
This is a retrospective study of prospectively kept record, 
which involved data analysis of records of RCC patients who 
presented to our institution from April 2016 to  February 
2020. All the patients had either contrast-enhanced com-
puterised tomography (CECT) scans or magnetic resonance 
imaging, where renal CECT was contraindicated for clinical 
staging and characterisation of the renal tumour. Laboratory 
investigations, including tests for paraneoplastic syndrome 
(PNS), were performed, and treatment was offered according 
to the stage, patient factors and available modalities. Renal 
masses diagnosed as benign were excluded from the analysis. 
The seventh and eighth edition of the American Joint Com-
mittee on Cancer tumour, nodes and metastasis (TNM) stag-
ing systems were used to classify cancer stage and grade (5); 
the seventh edition for cases managed before January 2018 
and the eighth edition for cases managed after January 2018. 
The histological subtypes were classified as per the classifi-
cation of World Health Organization for renal tumours, 
2016 (6).
Results
A total of 142 patients vising the institute were diagnosed 
with RCC, of which 104 patients were male and 38 patients 
were female. Most patients presented were in the sixth and 
seventh decades, 43 patients (30.2%) were below 50 years 
of age. 58 years being the median age at presentation, the 
youngest patient was 20-year-old and the oldest was 84-year-
old (Table 1). Right- and left-sided RCC were equally dis-
tributed, and three patients had bilateral tumours. In our 
study, in many patients, the renal mass was detected inciden-
tally (34%). In symptomatic patients, haematuria (29%) and 
abdominal pain (24%) were the most common complaints 
Table 1: Age at presentation.
S. No. Age group No. of patients (n = 142)








(Figure 1). Nearly 25.6% of the patients had comorbidities, 
hypertension (HTN) (n = 22) and diabetes mellitus (DM) 
(n = 17) being the most common (Table 2). PNSs were seen 
in 56.3% (n = 80) of the patients, with raised erythrocyte sed-
imentation rate (ESR) (n = 50) being the most common PNS 
(Figure 2). At presentation, 106 (74.6%) patients were treat-
ment naïve, 31 (21.8%) patients had undergone radical or 
partial nephrectomy, and 5 (3%) patients had received tyro-
sine kinase inhibitor (TKI) elsewhere before coming to our 
centre. Of the 106 treatment naïve patients, 97 underwent 
surgery as their initial mode of treatment, 9 received TKI 
upfront and 2 received TKI after cytoreductive nephrectomy. 
None of the patients who received TKI upfront were deemed 
fit for any surgical intervention later on. Radical nephrec-
tomy was done in 73 patients, nephron sparing surgery (NSS) 
in 21 patients and cytoreductive nephrectomy in 3 patients. 
Most of the radical nephrectomies in our centre were min-
imally invasive, with conversion to open procedure in three 
cases. Only cases that were more than 20 cm or involving the 
adjacent organs or with inferior vena cava (IVC) involve-
ment (level 2) were planned for open surgeries. NSS done in 
the initial years were open surgeries, but as our institution 
acquired the da Vinci robotic system, all the NSS in 2019 
were robot assisted, of which one was converted to open. 
The decision to perform NSS was based on the tumour char-
acteristics, patient factors and patient’s choice (Figure  3). 
Lymph node dissection was done in four cases, of which one 
case had metastatic deposits. The disease was organ con-
fined (pT1 and pT2) in 93 (65.9%) patients; however, only 26 
patients had a tumour size of <4 cm (pT1a). IVC thrombus 
was seen in 13 patients, most common being level 1 (n = 7), 
followed by level 2 (n = 4) and level 4 (n = 2). There was no 
significant difference in clinical stage of the tumour, tumour 
size, tumour grade, presence of lymph nodes and IVC throm-
bus in different age groups (Table 3). Of the 106 patients who 
were treatment naïve, the most common histopathologic 
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S. No. Comorbidities No. of patients 
(n = 48)
1 Hypertension 22
2 Diabetes mellitus 17
3 von Hippel Lindau syndrome 2
4 Coronary artery disease 3




in 2 adjuvant treatment was indicated and chemotherapy 
(gemcitabine + doxorubicin) was administered, both at 12 
months follow-up were recurrence free.
Discussion
According to available literature, RCC is a disease of elderly 
population (7). Although data from a developing country 
like India are limited, as per the SEER database, almost 50% 
patients with RCC present in the age group between 55 and 
75 years and the median age at presentation is 64 years (8). 
The median age of presentation in this study was 58 years, 
with one-fourth (26.7%) of the patients less than 50 years 
of age, and 14% below 40 years of age. This shows a much 
younger age of presentation in this area. These findings are 
similar to other Indian studies and Asian studies (4, 9–14). 
Asian population has a reportedly low incidence of RCC, 
which may be multifactorial, including genetic and environ-
mental factors or other factors like low reporting (15). The 
younger age of presentation may also be attributable to envi-
ronmental factors, dietary factors or genetic susceptibility, 
which needs to be conclusively addressed by larger epidemio-
logical studies (16). As per existing literature from developed 
world, the male to female ratio of RCC patients is 2:1 (17). 
We found an even higher incidence of renal cancers in males, 
with a male to female ratio of 2.7:1. This finding is similar 
to that of other Indian studies (2.9) and Asian countries 
(13, 18). This may be due to the lower incidence of smoking 
among women or low socioeconomic conditions, leading to 
difference in treatment seeking behaviour (19).
In our study, most of the patients were symptomatic 
(67%) with most common presenting symptom being 
type of RCC was clear cell carcinoma, comprising 73 (68.8%) 
cases, followed by papillary (20%) and chromophobe car-
cinoma (8%). The other rare tumours were peripheral neu-
roectodermal tumour (PNET) (n = 2), tubulocystic RCC 
(n = 1) mucinous tubular and spindle cell carcinoma (n = 1) 
and solitary fibrous tumour (n = 1) (Table 4). Although clear 
cell RCC was the most common histologic type in younger 
age group patients (<50 years), seen in 70% (n = 19) of the 
patients, the uncommon histologic types were also seen most 
commonly in this age group. Two patients with sarcomatoid 
differentiation and two patients with multicystic variant were 
both <50 years old. Three patients had von Hippel Lindau 
syndrome, of which two patients had bilateral multiple 
tumours. One patient with bilateral tumours was managed 
with cytoreductive nephrectomy and adjuvant TKI and the 
other patient was managed with upfront TKI and close fol-
low-up. Of total 5 patients with sarcomatoid differentiation, 
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Table 3: Stage at presentation.






















Figure 2: Paraneoplastic syndrome.
haematuria (28%) followed by pain abdomen (24%), and inci-
dentally diagnosed RCC accounting for only 33%. This is in 
contrast to findings in Western studies where more than 60% 
of renal cancers are diagnosed incidentally (20). The inci-
dence of incidental RCC is still higher in our data compared 
with other Indian studies (4). Similar findings have been 
noted in another Indian study (21). This could be due to the 
changing trend towards earlier detection of RCC in India.
It has been established in literature that approximately 
20% of patients with RCC develop PNSs (22, 23). These data 
have predominantly been derived from Western population. 
In our study, 56.3% patients developed PNS, with raised ESR 
being the most common (62.5%), followed by hypertension 
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histological pattern, with higher chances of aggressive carci-
noma. Stage at presentation in our patients was also different 
from those in the West. SEER data suggest that 60–70% of 
their patients present at Stage 1 (8), but in our study only 
40% cases presented at Stage 1 and 65.5% of patients pre-
sented at Stages 1 and 2, this shows an advanced stage at 
presentation of patients with RCC in India compared with 
Western counterparts where they present at a much earlier 
stage. This is also reflected in the lower proportion of partial 
nephrectomies done in this study. Interestingly though, the 
proportion of patients presenting with localised carcinoma 
is much higher in this study that other Indian studies (4, 10). 
This could be because of increased imaging performed in 
recent years, with widespread use of cross-sectional imaging.
The number of radical nephrectomies done in this study 
far outweighs the NSS. This is probably due to the higher 
stage of presentation in our population. Laparoscopic rad-
ical nephrectomies were the standard of care rather than 
exception in our study. Our experience with the laparoscopic 
surgery has been positive with low open conversion rate (5%) 
and low morbidity from surgeries. Although the traditional 
indications for laparoscopic radical nephrectomy are for 
localised carcinoma (size up to 10–12 cm) (14), we believe 
there is further scope for expanding these indications to t2b 
and t3a tumours. Open surgeries still play a role in difficult 
nephrectomies, for T3b and T3c tumours, and large RCC 
>15 cm in maximum dimension where placing ports can be 
difficult; but the indications for it are shrinking day by day. 
Management of nonlocalised RCC and syndromic patients 
was discussed in multidisciplinary team and TKI and che-
motherapy were used as neo-adjuvant, adjuvant or only 
treatment modality, according to disease and patient factors.
The limitations of this study are that it was a retrospective 
study, with smaller number of patients, a few of the patients 
were operated elsewhere and came to our institution for fur-
ther management and/or follow-up, and detailed follow-up 
was not available.
Conclusion
In our study, a significant number of patients were asymp-
tomatic, in which RCC was detected incidentally. The age 
of presentation was earlier, yet the patients had a higher 
tumour stage. More than half  of the patients had PNS. Clear 
cell RCC was the most common histologic type, though less 
common than that is reported in literature. More number 
of patients less than 50 years of age had sarcomatoid differ-
entiation, with unusual presentations being more common. 
In conclusion, the findings suggest a growing trend towards 
Western data. However, the significantly higher number of 
patients with PNS suggests inherent differences in tumour 
biology, possibly related to differences in genetic and envi-
ronmental factors.
(25%), anaemia (17%), deranged LFTs (16%), thrombocy-
tosis (12%), polycythaemia (4%) and hypercalcaemia (3%). 
The postulated mechanisms for PNS in RCCs are elevated 
cytokines (especially IL-6), tumour secreting hepatotoxins 
and lysozymes (hepatic dysfunction/Stauffer syndrome), 
renin and IL-6 secretion by tumour cells (hypertension), 
erythropoietin secretion by tumour cells (polycythaemia), 
thrombopoietin secretion by tumour cells (thrombocyto-
sis), chronic disease, poor nutritional status and increased 
iron-binding protein Lactoferrin (anaemia)  (21). Immuno-
histochemistry (IHC) is not routinely applied to the tumour 
slides for demonstration of tumour cell production of the 
paraneoplastic agent. Interestingly, hypercalcaemia, which 
has been noted to be a common PNS in RCC, was found 
to be the least common in our study (15, 24). This study is 
the first that highlights the incidence of PNS in the Indian 
population, and the figure is significantly higher. The reason 
for the high incidence of PNS could be higher stage of pre-
sentation in Indian population, or it could be due to genetic 
or environmental factors, which need to be further studied.
With respect to histopathology and stage, there are varied 
data published in the Indian population. The data of histo-
pathology from Western countries show clear cell RCC to 
be the most common variant, accounting for close to 85% 
(25,  26). In our study, clear cell RCC accounted for only 
68.8% of all tumours. In patients less than 50 years of age, 
the multicystic variant was more common than in older 
patients. Moreover, 40% of the patients with sarcomatoid 
differentiation (2/5) were also <50 years of age. These find-
ings are in variance from those of other Indian studies (4, 
10), and from most of the Asian studies (12, 18), which show 
similar findings as those from the Western population. Only 
one other Indian study shows similar findings (9). In addi-
tion, in our study population, younger patients had varied 
Table 4: Histopathology in patients <50 years of age.
S. No. Type of RCC Number (n = 25)
1 Clear cell carcinoma 13
2 Sarcomatoid variant of 
clear cell carcinoma
2
3 Multicystic variant of clear 
cell carcinoma
2
4 Papillary carcinoma 3
5 Chromophobe carcinoma 2
6 Tubulocystic RCC 1
7 PNET of kidney 1
8 Solitary fibrous tumour 1
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